INS and Hyperglycemia: Furthermore, concerns remain regarding risks of fluid overload, hypoglycemia induced by insulin therapy in DKA management, and rebound hyperglycemia in hypoglycemia correction, highlighting the need for a critical synthesis of available evidence [8].